Management

Dr. Solomon S. Steiner
Chairman, President and Chief Executive Officer

Dr. Solomon S. Steiner co-founded our company and has served as our Chairman, President and Chief Executive Officer since our inception in December 2003. In 1991, Dr. Steiner founded Pharmaceutical Discovery Corporation, or PDC, a biopharmaceutical corporation. Dr. Steiner served as PDC’s Chief Executive Officer and Chairman of the Board of Directors from its inception until December 2001, when PDC was merged with two other companies to form MannKind Corporation. From December 2001 to February 2003, Dr. Steiner served on MannKind’s board of directors and as a Corporate Vice President and Chief Scientific Officer. In 1985, Dr. Steiner founded and was the Chairman of the Board of Directors and President of Clinical Technologies Associates, Inc., or CTAI, now known as Emisphere Technologies, Inc. Under his leadership CTAI went public in February of 1989. Dr. Steiner is an inventor of Emisphere’s oral delivery system for peptides and mucopolysaccharides. Dr. Steiner is currently an adjunct full professor at New York Medical College and research full professor of psychiatry and neurology at New York University School of Medicine. Dr. Steiner received a Ph.D. from New York University.

Mr. Gerard J. Michel
Chief Financial Officer, Vice President of Corporate Development and Treasurer

Mr. Gerard J. Michel has served as our Chief Financial Officer, Vice President of Corporate Development and Treasurer, since November 2007. Prior to joining Biodel, Mr. Michel served in various roles at NPS Pharmaceuticals, most recently as its Chief Financial Officer and Vice President of Corporate Strategy. Previously, Mr. Michel was a principal with the consulting firm of Booz-Allen & Hamilton where he evaluated and solved strategic and operational issues for healthcare clients. Mr. Michel also served in marketing, sales, and corporate development positions, both domestic and international with Lederle Labs. Mr. Michel received an M.S. in microbiology and an M.B.A., both from the University of Rochester.

Dr. Alan S. Krasner
Chief Medical Officer

Dr. Alan S. Krasner serves as our Chief Medical Officer. Prior to joining Biodel, Dr. Krasner served as Director in the Department of Clinical Research, Metabolic Diseases at Pfizer Global Research and Development, where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner is also a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut. Dr. Krasner received a B.S. from Northwestern University where he was in an Honors Program in medical education and an M.D. from Northwestern University Medical School. Dr. Krasner completed his residency at Johns Hopkins Hospital in internal medicine and subsequently received a fellowship from Johns Hopkins Hospital in endocrinology and metabolism.